Older patients (aged ≥60 years) with previously untreated advanced-stage classical Hodgkin lymphoma: a detailed analysis from the phase III ECHELON-1 study

Autor: Andres Forero-Torres, Tatyana Feldman, Christopher Pocock, Andrea Gallamini, John Radford, Joseph Tuscano, Yasuhiro Oki, Andrew M. Evens, Hina Jolin, Anas Younes, Keenan Fenton, Stephen M. Ansell, Joseph M. Connors, Andrew Grigg, Won Seog Kim, Ashish Gautam, Kerry J. Savage, Rachael Liu, Monika Długosz-Danecka
Rok vydání: 2021
Předmět:
Zdroj: Evens, A M, Connors, J M, Younes, A, Ansell, S M, Kim, W S, Radford, J, Feldman, T, Tuscano, J, Savage, K J, Oki, Y, Grigg, A, Pocock, C, Dlugosz-Danecka, M, Fenton, K, Forero-Torres, A, Liu, R, Jolin, H, Gautam, A & Gallamini, A 2021, ' Older patients (aged ≥60 years) with previously untreated advanced-stage classical Hodgkin lymphoma : a detailed analysis from the phase III ECHELON-1 study ', Haematologica . https://doi.org/10.3324/haematol.2021.278438
ISSN: 1592-8721
0390-6078
Popis: Effective and tolerable treatments are needed for older patients with classical Hodgkin lymphoma. We report results for older patients with classical Hodgkin lymphoma treated in the large phase III ECHELON-1 study of frontline brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (A+AVD) versus doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD). Modified progression-free survival per independent review facility for older versus younger patients (aged ≥60 vs.
Databáze: OpenAIRE